Agendia’s molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans.
MammaPrint®, Agendia’s main product for breast cancer, analyzes tumors based on a 70 gene signature and offers innovative, unbiased and clinically significant insight into tumor biology. It is the first FDA cleared breast cancer gene profiling assay of its kind and provides a highly accurate determination of metastasis risk (low or high) and distant recurrence within 10 years.
Twitter: http://www.twitter.com/Agendia
Facebook: http://www.facebook.com/AgendiaInc
YouTube: http://www.youtube.com/AgendiaInc
Specialties
Molecular Diagnostics in field of cancer
